Skip to main content
Erschienen in: Current Treatment Options in Oncology 1/2012

01.03.2012 | Endocrine Tumors (O Clark and A Dackiw, Section Editors)

Extent of Surgery for Papillary Thyroid Cancer: Preoperative Imaging and Role of Prophylactic and Therapeutic Neck Dissection

verfasst von: Robin M. Cisco, MD, Wen T. Shen, MD, Jessica E. Gosnell, MD

Erschienen in: Current Treatment Options in Oncology | Ausgabe 1/2012

Einloggen, um Zugang zu erhalten

Opinion statement

Papillary thyroid cancer (PTC) has an excellent prognosis, yet lymph node metastases are common. Most authors agree that central and/or lateral lymph node dissection should be undertaken in patients with abnormal lymph nodes detected on ultrasound, physical examination or intraoperative inspection. However the appropriate extent of prophylactic lymph node dissection for clinically node-negative patients remains the subject of controversy. There have been no randomized trials to date to offer guidance on this issue. The 2006 guidelines of the American Thyroid Association recommended consideration of prophylactic bilateral central lymph node dissection (CLND) for all patients undergoing thyroidectomy for PTC. However, the absence of compelling evidence for a benefit in terms of recurrence or survival, and the potential for increased morbidity, have led many, including our institution, to take an approach of selective central lymph node dissection. This approach is guided by the detection of abnormal lymph nodes on preoperative ultrasound, on physical examination, or during surgery. Postoperatively, ultrasound by an experienced ultrasonographer is the mainstay of evaluation for lymph node recurrence and is combined with monitoring of thyroglobulin and antithyroglobulin antibody levels. Reoperative lymph node dissection is typically undertaken upon detection and fine needle aspiration (FNA) of involved lymph nodes 0.8 cm or greater in size.
Literatur
2.
Zurück zum Zitat Fraker DL. Radiation exposure and other factors that predispose to human thyroid neoplasm. Surg Clin North Am. 1995;75:365–75.PubMed Fraker DL. Radiation exposure and other factors that predispose to human thyroid neoplasm. Surg Clin North Am. 1995;75:365–75.PubMed
3.
Zurück zum Zitat Kebebew E, et al. The prevalence and prognostic value of BRAF mutation in thyroid cancer. Ann Surg. 2007;246(3):466–70. discussion 470-1.PubMedCrossRef Kebebew E, et al. The prevalence and prognostic value of BRAF mutation in thyroid cancer. Ann Surg. 2007;246(3):466–70. discussion 470-1.PubMedCrossRef
4.
Zurück zum Zitat Hundahl SA, et al. A National Cancer Data Base report on 53,856 cases of thyroid carcinoma treated in the U.S., 1985-1995 [see commetns]. Cancer. 1998;83(12):2638–48.PubMedCrossRef Hundahl SA, et al. A National Cancer Data Base report on 53,856 cases of thyroid carcinoma treated in the U.S., 1985-1995 [see commetns]. Cancer. 1998;83(12):2638–48.PubMedCrossRef
5.
Zurück zum Zitat Lundgren CI, et al. Clinically significant prognostic factors for differentiated thyroid carcinoma: a population-based, nested case-control study. Cancer. 2006;106(3):524–31.PubMedCrossRef Lundgren CI, et al. Clinically significant prognostic factors for differentiated thyroid carcinoma: a population-based, nested case-control study. Cancer. 2006;106(3):524–31.PubMedCrossRef
6.
Zurück zum Zitat Kim TH, et al. The association of the BRAF(V600E) mutation with prognostic factors and poor clinical outcome in papillary thyroid cancer: A Meta-Analysis. Cancer. 2011. Kim TH, et al. The association of the BRAF(V600E) mutation with prognostic factors and poor clinical outcome in papillary thyroid cancer: A Meta-Analysis. Cancer. 2011.
7.
Zurück zum Zitat Bilimoria KY, et al. Extent of surgery affects survival for papillary thyroid cancer. Ann Surg. 2007;246(3):375–81. discussion 381-4.PubMedCrossRef Bilimoria KY, et al. Extent of surgery affects survival for papillary thyroid cancer. Ann Surg. 2007;246(3):375–81. discussion 381-4.PubMedCrossRef
8.
9.
Zurück zum Zitat Noguchi S, Noguchi A, Murakami N. Papillary carcinoma of the thyroid. I. Developing pattern of metastasis. Cancer. 1970;26(5):1053–60.PubMedCrossRef Noguchi S, Noguchi A, Murakami N. Papillary carcinoma of the thyroid. I. Developing pattern of metastasis. Cancer. 1970;26(5):1053–60.PubMedCrossRef
10.
Zurück zum Zitat Wada N, et al. Lymph node metastasis from 259 papillary thyroid microcarcinomas: frequency, pattern of occurrence and recurrence, and optimal strategy for neck dissection. Ann Surg. 2003;237(3):399–407.PubMed Wada N, et al. Lymph node metastasis from 259 papillary thyroid microcarcinomas: frequency, pattern of occurrence and recurrence, and optimal strategy for neck dissection. Ann Surg. 2003;237(3):399–407.PubMed
11.
Zurück zum Zitat Pellegriti G, et al. Clinical behavior and outcome of papillary thyroid cancers smaller than 1.5 cm in diameter: study of 299 cases. J Clin Endocrinol Metab. 2004;89(8):3713–20.PubMedCrossRef Pellegriti G, et al. Clinical behavior and outcome of papillary thyroid cancers smaller than 1.5 cm in diameter: study of 299 cases. J Clin Endocrinol Metab. 2004;89(8):3713–20.PubMedCrossRef
12.
Zurück zum Zitat Pereira JA, et al. Nodal yield, morbidity, and recurrence after central neck dissection for papillary thyroid carcinoma. Surgery. 2005;138(6):1095–100. discussion 1100-1.PubMedCrossRef Pereira JA, et al. Nodal yield, morbidity, and recurrence after central neck dissection for papillary thyroid carcinoma. Surgery. 2005;138(6):1095–100. discussion 1100-1.PubMedCrossRef
13.
Zurück zum Zitat Hay ID, et al. Papillary thyroid microcarcinoma: a study of 535 cases observed in a 50-year period. Surgery. 1992;112(6):1139–46. discussion 1146-7.PubMed Hay ID, et al. Papillary thyroid microcarcinoma: a study of 535 cases observed in a 50-year period. Surgery. 1992;112(6):1139–46. discussion 1146-7.PubMed
14.
Zurück zum Zitat Spires JR, et al. Metastatic papillary carcinoma of the thyroid: the significance of extranodal extension. Head Neck. 1989;11(3):242–6.PubMedCrossRef Spires JR, et al. Metastatic papillary carcinoma of the thyroid: the significance of extranodal extension. Head Neck. 1989;11(3):242–6.PubMedCrossRef
15.
Zurück zum Zitat Harwood J, Clark OH, Dunphy JE. Significance of lymph node metastasis in differentiated thyroid cancer. Am J Surg. 1978;136(1):107–12.PubMedCrossRef Harwood J, Clark OH, Dunphy JE. Significance of lymph node metastasis in differentiated thyroid cancer. Am J Surg. 1978;136(1):107–12.PubMedCrossRef
16.
Zurück zum Zitat Choi JS, et al. Preoperative staging of papillary thyroid carcinoma: comparison of ultrasound imaging and CT. AJR Am J Roentgenol. 2009;193(3):871–8.PubMedCrossRef Choi JS, et al. Preoperative staging of papillary thyroid carcinoma: comparison of ultrasound imaging and CT. AJR Am J Roentgenol. 2009;193(3):871–8.PubMedCrossRef
17.
Zurück zum Zitat Stulak JM, et al. Value of preoperative ultrasonography in the surgical management of initial and reoperative papillary thyroid cancer. Arch Surg. 2006;141(5):489–94. discussion 494-6.PubMedCrossRef Stulak JM, et al. Value of preoperative ultrasonography in the surgical management of initial and reoperative papillary thyroid cancer. Arch Surg. 2006;141(5):489–94. discussion 494-6.PubMedCrossRef
18.
Zurück zum Zitat Choi YJ, et al. Clinical and imaging assessment of cervical lymph node metastasis in papillary thyroid carcinomas. World J Surg. 2010;34(7):1494–9.PubMedCrossRef Choi YJ, et al. Clinical and imaging assessment of cervical lymph node metastasis in papillary thyroid carcinomas. World J Surg. 2010;34(7):1494–9.PubMedCrossRef
19.
Zurück zum Zitat Park JS, et al. Performance of preoperative sonographic staging of papillary thyroid carcinoma based on the sixth edition of the AJCC/UICC TNM classification system. AJR Am J Roentgenol. 2009;192(1):66–72.PubMedCrossRef Park JS, et al. Performance of preoperative sonographic staging of papillary thyroid carcinoma based on the sixth edition of the AJCC/UICC TNM classification system. AJR Am J Roentgenol. 2009;192(1):66–72.PubMedCrossRef
20.••
Zurück zum Zitat Cooper, D.S., et al., Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid, 2009. 19(11): p. 1167-214.PubMedCrossRef Cooper, D.S., et al., Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid, 2009. 19(11): p. 1167-214.PubMedCrossRef
21.
Zurück zum Zitat Sywak M, et al. Routine ipsilateral level VI lymphadenectomy reduces postoperative thyroglobulin levels in papillary thyroid cancer. Surgery. 2006;140(6):1000–5. discussion 1005-7.PubMedCrossRef Sywak M, et al. Routine ipsilateral level VI lymphadenectomy reduces postoperative thyroglobulin levels in papillary thyroid cancer. Surgery. 2006;140(6):1000–5. discussion 1005-7.PubMedCrossRef
22.•
Zurück zum Zitat Hughes, D.T., et al., Influence of prophylactic central lymph node dissection on postoperative thyroglobulin levels and radioiodine treatment in papillary thyroid cancer. Surgery, 2010. 148(6): p. 1100-6; discussion 1006-7.PubMedCrossRef Hughes, D.T., et al., Influence of prophylactic central lymph node dissection on postoperative thyroglobulin levels and radioiodine treatment in papillary thyroid cancer. Surgery, 2010. 148(6): p. 1100-6; discussion 1006-7.PubMedCrossRef
23.
Zurück zum Zitat Roh JL, Park JY, Park CI. Total thyroidectomy plus neck dissection in differentiated papillary thyroid carcinoma patients: pattern of nodal metastasis, morbidity, recurrence, and postoperative levels of serum parathyroid hormone. Ann Surg. 2007;245(4):604–10.PubMedCrossRef Roh JL, Park JY, Park CI. Total thyroidectomy plus neck dissection in differentiated papillary thyroid carcinoma patients: pattern of nodal metastasis, morbidity, recurrence, and postoperative levels of serum parathyroid hormone. Ann Surg. 2007;245(4):604–10.PubMedCrossRef
24.
Zurück zum Zitat Bardet S, et al. Macroscopic lymph-node involvement and neck dissection predict lymph-node recurrence in papillary thyroid carcinoma. Eur J Endocrinol. 2008;158(4):551–60.PubMedCrossRef Bardet S, et al. Macroscopic lymph-node involvement and neck dissection predict lymph-node recurrence in papillary thyroid carcinoma. Eur J Endocrinol. 2008;158(4):551–60.PubMedCrossRef
25.
Zurück zum Zitat Gemsenjager E, et al. Lymph node surgery in papillary thyroid carcinoma. J Am Coll Surg. 2003;197(2):182–90.PubMedCrossRef Gemsenjager E, et al. Lymph node surgery in papillary thyroid carcinoma. J Am Coll Surg. 2003;197(2):182–90.PubMedCrossRef
26.••
Zurück zum Zitat Zetoune, T., et al., Prophylactic central neck dissection and local recurrence in papillary thyroid cancer: a meta-analysis. Ann Surg Oncol, 2010. 17(12): p. 3287-93.PubMedCrossRef Zetoune, T., et al., Prophylactic central neck dissection and local recurrence in papillary thyroid cancer: a meta-analysis. Ann Surg Oncol, 2010. 17(12): p. 3287-93.PubMedCrossRef
27.
Zurück zum Zitat Tisell LE, et al. Improved survival of patients with papillary thyroid cancer after surgical microdissection. World J Surg. 1996;20(7):854–9.PubMedCrossRef Tisell LE, et al. Improved survival of patients with papillary thyroid cancer after surgical microdissection. World J Surg. 1996;20(7):854–9.PubMedCrossRef
28.
Zurück zum Zitat Henry JF, et al. Morbidity of prophylactic lymph node dissection in the central neck area in patients with papillary thyroid carcinoma. Langenbecks Arch Surg. 1998;383(2):167–9.PubMed Henry JF, et al. Morbidity of prophylactic lymph node dissection in the central neck area in patients with papillary thyroid carcinoma. Langenbecks Arch Surg. 1998;383(2):167–9.PubMed
29.
Zurück zum Zitat Palestini N, et al. Is central neck dissection a safe procedure in the treatment of papillary thyroid cancer? Our experience. Langenbecks Arch Surg. 2008;393(5):693–8.PubMedCrossRef Palestini N, et al. Is central neck dissection a safe procedure in the treatment of papillary thyroid cancer? Our experience. Langenbecks Arch Surg. 2008;393(5):693–8.PubMedCrossRef
30.
Zurück zum Zitat Mazzaferri EL, Doherty GM, Steward DL. The pros and cons of prophylactic central compartment lymph node dissection for papillary thyroid carcinoma. Thyroid. 2009;19(7):683–9.PubMedCrossRef Mazzaferri EL, Doherty GM, Steward DL. The pros and cons of prophylactic central compartment lymph node dissection for papillary thyroid carcinoma. Thyroid. 2009;19(7):683–9.PubMedCrossRef
31.
Zurück zum Zitat Roh JL, Kim JM, Park CI. Lateral cervical lymph node metastases from papillary thyroid carcinoma: pattern of nodal metastases and optimal strategy for neck dissection. Ann Surg Oncol. 2008;15(4):1177–82.PubMedCrossRef Roh JL, Kim JM, Park CI. Lateral cervical lymph node metastases from papillary thyroid carcinoma: pattern of nodal metastases and optimal strategy for neck dissection. Ann Surg Oncol. 2008;15(4):1177–82.PubMedCrossRef
32.
Zurück zum Zitat Shen WT, et al. Central neck lymph node dissection for papillary thyroid cancer: the reliability of surgeon judgment in predicting which patients will benefit. Surgery. 2010;148(2):398–403.PubMedCrossRef Shen WT, et al. Central neck lymph node dissection for papillary thyroid cancer: the reliability of surgeon judgment in predicting which patients will benefit. Surgery. 2010;148(2):398–403.PubMedCrossRef
33.
Zurück zum Zitat Forest VI, et al. Central compartment dissection in thyroid papillary carcinoma. Ann Surg. 2011;253(1):123–30.PubMedCrossRef Forest VI, et al. Central compartment dissection in thyroid papillary carcinoma. Ann Surg. 2011;253(1):123–30.PubMedCrossRef
34.
Zurück zum Zitat Jonklaas J, et al. Outcomes of patients with differentiated thyroid carcinoma following initial therapy. Thyroid. 2006;16(12):1229–42.PubMedCrossRef Jonklaas J, et al. Outcomes of patients with differentiated thyroid carcinoma following initial therapy. Thyroid. 2006;16(12):1229–42.PubMedCrossRef
35.
Zurück zum Zitat Sippel RS, et al. Localization of recurrent thyroid cancer using intraoperative ultrasound-guided dye injection. World J Surg. 2009;33(3):434–9.PubMedCrossRef Sippel RS, et al. Localization of recurrent thyroid cancer using intraoperative ultrasound-guided dye injection. World J Surg. 2009;33(3):434–9.PubMedCrossRef
36.
Zurück zum Zitat Shen WT, et al. Central neck lymph node dissection for papillary thyroid cancer: comparison of complication and recurrence rates in 295 initial dissections and reoperations. Arch Surg. 2010;145(3):272–5.PubMedCrossRef Shen WT, et al. Central neck lymph node dissection for papillary thyroid cancer: comparison of complication and recurrence rates in 295 initial dissections and reoperations. Arch Surg. 2010;145(3):272–5.PubMedCrossRef
37.
Zurück zum Zitat Takami H, et al. Therapeutic strategy for differentiated thyroid carcinoma in Japan based on a newly established guideline managed by Japanese Society of Thyroid Surgeons and Japanese Association of Endocrine Surgeons. World J Surg. 2011;35(1):111–21.PubMedCrossRef Takami H, et al. Therapeutic strategy for differentiated thyroid carcinoma in Japan based on a newly established guideline managed by Japanese Society of Thyroid Surgeons and Japanese Association of Endocrine Surgeons. World J Surg. 2011;35(1):111–21.PubMedCrossRef
38.
Zurück zum Zitat Ito Y, et al. An observational trial for papillary thyroid microcarcinoma in Japanese patients. World J Surg. 2010;34(1):28–35.PubMedCrossRef Ito Y, et al. An observational trial for papillary thyroid microcarcinoma in Japanese patients. World J Surg. 2010;34(1):28–35.PubMedCrossRef
Metadaten
Titel
Extent of Surgery for Papillary Thyroid Cancer: Preoperative Imaging and Role of Prophylactic and Therapeutic Neck Dissection
verfasst von
Robin M. Cisco, MD
Wen T. Shen, MD
Jessica E. Gosnell, MD
Publikationsdatum
01.03.2012
Verlag
Current Science Inc.
Erschienen in
Current Treatment Options in Oncology / Ausgabe 1/2012
Print ISSN: 1527-2729
Elektronische ISSN: 1534-6277
DOI
https://doi.org/10.1007/s11864-011-0175-z

Weitere Artikel der Ausgabe 1/2012

Current Treatment Options in Oncology 1/2012 Zur Ausgabe

Endocrine Tumors (O Clark and A Dackiw, Section Editors)

Parathyroid Carcinoma: Update and Guidelines for Management

Head and Neck Cancer (T Day, Section Editor)

Recurrent Salivary Gland Cancer

Endocrine Tumors (O Clark and A Dackiw, Section Editors)

Neuroendocrine Pancreatic Tumors: Guidelines for Management and Update

„Überwältigende“ Evidenz für Tripeltherapie beim metastasierten Prostata-Ca.

22.05.2024 Prostatakarzinom Nachrichten

Patienten mit metastasiertem hormonsensitivem Prostatakarzinom sollten nicht mehr mit einer alleinigen Androgendeprivationstherapie (ADT) behandelt werden, mahnt ein US-Team nach Sichtung der aktuellen Datenlage. Mit einer Tripeltherapie haben die Betroffenen offenbar die besten Überlebenschancen.

So sicher sind Tattoos: Neue Daten zur Risikobewertung

22.05.2024 Melanom Nachrichten

Das größte medizinische Problem bei Tattoos bleiben allergische Reaktionen. Melanome werden dadurch offensichtlich nicht gefördert, die Farbpigmente könnten aber andere Tumoren begünstigen.

CAR-M-Zellen: Warten auf das große Fressen

22.05.2024 Onkologische Immuntherapie Nachrichten

Auch myeloide Immunzellen lassen sich mit chimären Antigenrezeptoren gegen Tumoren ausstatten. Solche CAR-Fresszell-Therapien werden jetzt für solide Tumoren entwickelt. Künftig soll dieser Prozess nicht mehr ex vivo, sondern per mRNA im Körper der Betroffenen erfolgen.

Blutdrucksenkung könnte Uterusmyome verhindern

Frauen mit unbehandelter oder neu auftretender Hypertonie haben ein deutlich erhöhtes Risiko für Uterusmyome. Eine Therapie mit Antihypertensiva geht hingegen mit einer verringerten Inzidenz der gutartigen Tumoren einher.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.